Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82b8ce8e71df155d570d141ceb42fdb0 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-54 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-54 |
filingDate |
2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2019-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08752abdfead4c7aa8d764b18eee04d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5042666db9488f7c4bcca31730638433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3db6d3b22616eb533d2b0badbbf91fca |
publicationDate |
2019-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10196425-B2 |
titleOfInvention |
Peptide compositions |
abstract |
The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): n nor a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021040155-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10960046-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018215790-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019092815-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10858399-B2 |
priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |